On May 18, 2016 Fortress Biotech (NASDAQ: FBIO), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, reported positive data from the Phase 1/2 study of CNDO‐109‐Activated Allogeneic Natural Killer (NK) Cells in patients with acute myeloid leukemia (AML) in their first complete remission who are at a high risk of relapsing (Press release, Fortress Biotech, MAY 18, 2016, View Source [SID:1234512522]). The data were presented yesterday in an oral session at the Innate Killer Summit 2016 in San Diego, CA. Schedule your 30 min Free 1stOncology Demo! Dr. Lindsay A. Rosenwald, Chairman, President and CEO of Fortress, said, "We are very pleased by the early safety profile demonstrated by CNDO‐109‐Activated NK Cells. Additionally, while designed primarily to determine the safety of CNDO‐109 in patients who were already in remission, we were encouraged to see three high‐risk patients treated at the higher dose cohorts remain in complete remission for approximately two years." Dr. Rosenwald continued, "We would like to thank the investigators who participated in this Phase 1/2 study for their efforts on this important research program."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CNDO‐109‐Activated Allogeneic Natural Killer (NK) Cells CNDO‐109 is a lysate (disrupted CTV‐1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells ex vivo. Fortress acquired exclusive worldwide rights to develop and commercialize CNDO‐109 activated NK cells for the treatment of cancer from University College London Business.
About Acute Myeloid Leukemia (AML)
AML is one of the deadliest and most common types of acute leukemia in adults. According to a Decision Resources report, there are more than 43,000 cases worldwide, primarily afflicting elderly and relapsed and refractory populations. Once diagnosed with AML, patients typically receive induction and consolidation chemotherapy, with the majority achieving complete remission. However, roughly 70–80 percent of patients who achieve first complete remission will relapse, and the overall five‐year survival rate is less than 25 percent.